A West Michigan man has been accused of selling misbranded weight loss drugs to U.S. consumers without a valid prescription.

Orforglipron, a new glucagon-like peptide-1 (GLP-1) receptor agonist pill, leads to greater glycaemic control and weight loss for patients with type 2 diabetes than oral semaglutide (Rybelsus), ...

Drugmaker Lilly said its experimental pill, orforglipron, produced better blood sugar and weight loss for diabetes patients results in a new head-to-head clinical trial.

A clinical trial for diabetes that pit orforglipron, a diabetes and weight-loss pill developed by Eli Lilly, against oral ...

Novo Nordisk NVO has endured a brutal week, with its shares plunging 21% after a series of disappointing clinical results and mounting pricing pressures erased virtually all the gains accumulated ...

Novo Nordisk slashes U.S. prices for Ozempic and Wegovy by up to 50%, reshaping access to diabetes and weight-loss care.

A new pill could help patients lose more weight and gain better control of their blood sugar levels than current weight loss medications, a promising new study has found.

“GLP‑1s have effectively created a third pillar of pharmacy spend and most employers don't yet have a mature playbook to manage it,” Conway said, adding that over half of employers now cite GLP‑1s as ...

Feb 26 (Reuters) - Eli Lilly's experimental weight-loss pill, orforglipron, caused more side effects and treatment ...

Feb 26 () - Eli Lilly on Thursday released new data from a head-to-head trial of its experimental weight-loss ‌pill, ...

Novo Nordisk reported a loss in a head-to-head trial of CagriSema against Lilly’s Zepbound earlier this week. This time around, Lilly's orforglipron bested Novo's oral semaglutide in blood sugar ...

Lilly’s new data show its oral GLP-1 beating Novo’s on major benchmarks.